NCT03860233View on ClinicalTrials.gov

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

December 1, 2025

Study Completion Date

March 1, 2026

Conditions
Sleep ApneaSleep Apnea, Obstructive
Interventions
DRUG

Oxytocin

40 IU administered intranasal, within 1 hour prior to sleeping for 14 days

DRUG

Placebo

Intranasal spray to mimic Oxytocin intranasal spray

Trial Locations (1)

20037

RECRUITING

Medical Faculty Associates, Washington D.C.

All Listed Sponsors
collaborator

George Washington University

OTHER

lead

Vivek Jain

OTHER

NCT03860233 - Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine | Biotech Hunter | Biotech Hunter